Lucerastat
≥98%
- Product Code: 101592
CAS:
141206-42-0
| Molecular Weight: | 219.28 g./mol | Molecular Formula: | C₁₀H₂₁NO₄ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, sealed, dry |
Product Description:
Lucerastat is primarily investigated for its potential therapeutic applications in treating rare genetic disorders, particularly those related to glycosphingolipid metabolism. It is being studied as a substrate reduction therapy agent for Fabry disease, a condition characterized by the accumulation of globotriaosylceramide (Gb3) due to enzyme deficiencies. By inhibiting an enzyme involved in glycosphingolipid synthesis, Lucerastat aims to reduce the buildup of harmful substrates in cells, potentially alleviating symptoms such as pain, kidney dysfunction, and cardiovascular complications. Its oral administration offers a convenient treatment option, and ongoing clinical trials are evaluating its efficacy and safety in improving patient outcomes.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Pale Brown Solid |
| Purity (%) | 97.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.001 | 10-20 days | $354.04 |
+
-
|
| 0.005 | 10-20 days | $1,368.14 |
+
-
|
Lucerastat
Lucerastat is primarily investigated for its potential therapeutic applications in treating rare genetic disorders, particularly those related to glycosphingolipid metabolism. It is being studied as a substrate reduction therapy agent for Fabry disease, a condition characterized by the accumulation of globotriaosylceramide (Gb3) due to enzyme deficiencies. By inhibiting an enzyme involved in glycosphingolipid synthesis, Lucerastat aims to reduce the buildup of harmful substrates in cells, potentially alleviating symptoms such as pain, kidney dysfunction, and cardiovascular complications. Its oral administration offers a convenient treatment option, and ongoing clinical trials are evaluating its efficacy and safety in improving patient outcomes.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :